Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)

1 Oct 2024

Abstract excerpt

BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic factors in colorectal cancer
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39354185
DOI: 10.1038/s41391-024-00901-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)PMID 39354185Read ↗

Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution.Semantic proximity Read ↗

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.Semantic proximity Read ↗

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutionsSemantic proximity Read ↗

Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate CancerSemantic proximity Read ↗

Germline and somatic mutations in prostate cancer: Implications for treatment.Semantic proximity Read ↗

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testingSemantic proximity Read ↗

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA RepairSemantic proximity Read ↗

Clinical implications of homologous recombination repair mutations in prostate cancer.Semantic proximity Read ↗

Germline mutations and prostate cancer: is it time to change treatment algorithms?Semantic proximity Read ↗

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing GuidelinesSemantic proximity Read ↗

Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.Semantic proximity Read ↗

Therapeutic targeting of the DNA damage response in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.